Logo
x

Search

Subscribe Now

Amarin

Amarin Entered into an Exclusive Commercialization Agreement with Neopharm for Vazkepa (Icosapent Ethyl) in Israel

Amarin Entered into an Exclusive Commercialization Agreement with Neopharm for Vazkepa (Icosapent Ethyl) in Israel

  • August 9, 2023
Amarin Entered into an Exclusive Agreement with Lotus Pharmaceuticals to Commercialize Vazkepa (icosapent ethyl) in Southeast Asia and South Korea

Amarin Entered into an Exclusive Agreement with Lotus Pharmaceuticals to Commercialize Vazkepa (icosapent ethyl) in Southeast Asia...

  • August 1, 2023
Amarin Entered into an Exclusive License and Distribution Agreement with CSL Seqirus to Commercialize Vazkepa (icosapent ethyl) In Australia and New Zealand

Amarin Entered into an Exclusive License and Distribution Agreement with CSL Seqirus to Commercialize Vazkepa (icosapent ethyl) In...

  • March 1, 2023
Amarin Reports (REDUCE-IT) Trial Results of Vascepa/Vazkepa (icosapent ethyl) for Cardiovascular Diseases

Amarin Reports (REDUCE-IT) Trial Results of Vascepa/Vazkepa (icosapent ethyl) for Cardiovascular Diseases

  • August 29, 2022
NICE Issues Final Guidance on Amarin’s Vazkepa (icosapent ethyl) for the Treatment of Cardiovascular Disease

NICE Issues Final Guidance on Amarin’s Vazkepa (icosapent ethyl) for the Treatment of Cardiovascular Disease

  • July 14, 2022
Amarin’s Vazkepa (icosapent ethyl) Receives NICE Recommendation for the Treatment of Cardiovascular Disease

Amarin’s Vazkepa (icosapent ethyl) Receives NICE Recommendation for the Treatment of Cardiovascular Disease

  • June 10, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.